| Abstrakt: |
This article provides a comprehensive overview of recent advancements in the treatment of hormonal receptor positive (HR+) breast cancer. It discusses various treatment options such as CDK4/6 inhibitors, PI3 kinase inhibitors, antibody drug conjugates, PARP inhibitors, and oral selective ER degraders. The article also explores the role of aromatase inhibitors in adjuvant treatment and the management of AI-induced arthralgia. Additionally, it discusses the potential of traditional Chinese medicine in preventing and treating osteoporosis caused by endocrine therapy. The document further covers various research topics related to breast cancer, including the cost-effectiveness of elacestrant, the prevalence of PIK3CA mutations in Taiwanese patients, the diagnostic potential of AGR2, the role of cancer-associated fibroblasts, predictors for chemotherapy response, the functions of Let-7i microRNA, and the potential benefits of diet and lifestyle changes. The article concludes by emphasizing the need for further research in these areas to improve breast cancer diagnosis and treatment. [Extracted from the article] |
